Therapy Area topics
The group continues its niche-targeting strategy with abelacimab’s latest pivotal trial.
A pivotal trial is in the works, but can the group succeed where other VEGF gene therapies have failed?
The group's pulmonary arterial hypertension therapy might work in sicker patients, but investors are unwilling to stick around.
Improving atrial fibrillation diagnosis is one thing; improving outcomes another.
But difficulties around reimbursement, selling and market value could make it hard for the app maker to live up to its name.
Young device makers were surprisingly appealing to VCs in the first half of 2022 – unless they were active in digital health.